Inhibition of Bruton’s tyrosine kinase (BTK), an ITK homolog required for antigen-receptor signaling in B cells, has transformed the therapeutic landscape in many B-cell lymphomas [43–45]. Here, BTK is linked to B-cell non-Hodgkin lymphoma.